Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has
completed the $1.0 billion stock repurchase program that was
authorized by its Board of Directors in March 2006. Under the buyback
program, Gilead acquired approximately 8.4 million shares of its
common stock at an average price of $65.13 per share, representing a
total of $544.9 million, in connection with a $1.3 billion convertible
notes offering completed in April 2006 and subsequently used the
remaining $455.1 million to acquire approximately 5.6 million shares
of common stock at an average price of $81.02 per share. Upon
completion of the stock repurchase program on June 18, 2007, the
company had approximately 468,090,700 shares outstanding, excluding
stock options and unvested restricted shares.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. The company's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia. For more information on Gilead Sciences, please
visit the company's website at www.gilead.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
For more information on Gilead, please call the Gilead Public
Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit
www.gilead.com.